The FDA usually follows the recommendations of its advisory panels. The panelists have been cleared of potential conflicts of interest related to the topic of the meeting. Occasionally, a panelist may be given a waiver but not at this meeting.
*Correction, 5/9/2012: A previous version of this story misstated the panelists' concern about the drug's potential to cause cancer.